President Donald Trump announced a significant expansion of the TrumpRx prescription drug discount program on Friday. The initiative now includes more than 800 medications available at reduced prices through the government-backed website TrumpRx.gov. The expansion adds 160 prescription drugs to the platform, which launched earlier this year as part of the administration’s effort to lower healthcare costs for Americans. Trump shared the update through his Truth Social account, emphasizing the program’s growing reach and potential savings for consumers across the country.
The president stated that the expanded program now covers four out of five prescriptions filled by Americans. The website provides transparent pricing information and discount coupons for participating medications. Users can search for specific drugs, view estimated savings, and generate coupons that can be used at participating pharmacies nationwide.
Most-favored-nation pricing agreements drive program expansion
The TrumpRx initiative operates through pricing agreements with 16 major pharmaceutical companies. These arrangements, known as “most-favored-nation” pricing deals, were finalized before the website’s February launch. Under the terms, participating drugmakers received tariff-related exemptions in exchange for lowering prices on certain medications and extending discounted pricing to eligible cash-paying consumers.
Major pharmaceutical companies including Eli Lilly and Novo Nordisk have joined the program. These companies agreed to reduce prices on popular GLP-1 weight-loss medications, which have seen significant demand in recent years. The program also features discounts on various other products across multiple therapeutic categories.
Wide range of medications included in discount program
Administration officials highlighted the breadth of medications covered by TrumpRx. The program includes discounts on essential treatments across several categories:
- Inhalers for respiratory conditions
- HIV treatment medications
- Diabetes management drugs
- Fertility drugs for reproductive health
- Weight-loss medications including GLP-1 treatments
The variety of medications reflects the administration’s goal to address prescription drug costs across different health conditions. The discounts apply to commonly prescribed medications that millions of Americans use regularly. The program targets both chronic condition treatments and specialized medications that often carry high price tags.
Trump claims substantial savings for American patients
The president stated that the most-favored-nation deals have generated over $400 million in savings for American patients since TrumpRx.gov launched. Trump emphasized the role of tariffs in securing these pricing agreements, arguing that other countries would now “pay up” instead of American patients bearing disproportionate costs. He described the previous situation as unfair and stated he ordered an immediate stop to what he called decades of Americans being overcharged for prescription drugs.
Trump also referenced his first term, noting that his administration made history by lowering drug prices, even by small percentages. He contrasted this with previous administrations that he claimed only raised drug prices significantly each year. The president said he decided to “go big” in his second term with most-favored-nation pricing, aiming to ensure Americans pay no more, or ideally less, than any other country for identical drugs.
Administration plans further expansion of discount program
Trump announced that he has instructed his administration to secure additional most-favored-nation deals with more pharmaceutical companies. The directive aims to expand partnerships and achieve lower prices for American patients across additional medication categories. The president stated the program represents significant progress but indicated plans to continue expanding the initiative’s scope and reach.
The administration frames the program as addressing long-standing price disparities where Americans historically paid more for prescription drugs than consumers in many other countries. Officials argue the tariff-linked agreements create leverage to negotiate better prices while providing relief to cash-paying consumers who often face the highest out-of-pocket costs. The program operates alongside existing insurance coverage and prescription benefit programs, offering an additional option for patients seeking lower medication costs.
